Vintafolide

Drug Profile

Vintafolide

Alternative Names: EC-145; Folic acid desacetylvinblastine hydrazine conjugate; MK-8109; VYNFINIT

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte
  • Class Amino acids; Antineoplastics; Folic-acids; Hydrazines; Pterins; Sulfhydryl compounds; Vinca alkaloids
  • Mechanism of Action Microtubule protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 07 Sep 2015 Final efficacy and adverse events data from a phase II trial in Non Small Cell Lung Cancer released by Endocyte
  • 01 Sep 2015 Discontinued - Phase-II for Endometrial cancer (Late-stage disease) in USA (IV)
  • 01 Aug 2015 Endocyte completes the phase IIb TARGET trial for Non-small cell lung cancer (Combination therapy, Monotherapy, Second-line therapy or greater) in USA, Bulgaria, the Czech Republic, France, Germany, Hungary, Poland, Romania, Russia, Spain and the UK (NCT01577654)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top